CompletedPhase 2NCT02678455

Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh

Studying Dengue fever

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator
Rashidul Haque, MD, MD
Centre for Vaccine Sciences, International Centre for Diarrhoeal Disease Research, Bangladesh
Intervention
TV005 vaccine(biological)
Enrollment
192 enrolled
Eligibility
50 years · All sexes
Timeline
2016 – 2020

Study locations (1)

Collaborators

University of Vermont · Johns Hopkins Bloomberg School of Public Health

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02678455 on ClinicalTrials.gov

Other trials for Dengue fever

Additional recruiting or active studies for the same condition.

See all trials for Dengue fever →

← Back to all trials